Cancer Immunotherapy Market

Cancer Immunotherapy Market Analysis By Therapy (Monoclonal Antibody, Immune Checkpoint Inhibitors, Immune System Modulators), By Type (Lung, Colorectal, Breast, Prostate, Melanoma, Blood Cancer), By End User, By Region - Global Insights to 2031

Analysis of Cancer Immunotherapy market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Table of Content

1.  Preface

   1.1. Market Definition and Scope

   1.2. Market Segmentation

   1.3. Key Research Objectives

   1.4. Research Highlights

2.  Assumptions and Research Methodology

3.  Executive Summary : Global Cancer Immunotherapy Market

4.  Market Overview

   4.1. Introduction

       4.1.1. Market Definition

       4.1.2. Industry Evolution / Developments

   4.2. Overview

   4.3. Key Market Indicators

       4.3.1. Region/Country Specific

       4.3.2. Product/Therapeutic Area Specific

       4.3.3. Target Market Specific – Global Scenario

   4.4. Market Dynamics

       4.4.1. Drivers

       4.4.2. Restraints

       4.4.3. Opportunity

       4.4.4. Trends

   4.5. Global Cancer Immunotherapy Market Analysis and Forecasts, 2021–2031

       4.5.1. Market Revenue Projections (US$ Mn)

   4.6. Cancer Immunotherapy Market - Global Supply Demand Scenario

   4.7. Porter’s Five Force Analysis

   4.8. Value Chain Analysis

       4.8.1. List of active market participants

           4.8.1.1. Manufacturers

           4.8.1.2. Distributors

       4.8.2. Forward – Backward Integration Scenario

   4.9. Market Outlook

   4.10. Pipeline Snapshot

   4.11. Cancer Epidemiology

   4.12. Reimbursement Scenario and Patient Support Programs Overview

5. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapy Type

   5.1. Introduction & Definition

   5.2. Key Findings / Developments

   5.3. Market Value Forecast By Therapy Type, 2021–2031

       5.3.1. Monoclonal Antibodies

       5.3.2. Immune Checkpoint Inhibitors

           5.3.2.1. PD-1/PD-L1

           5.3.2.2. CTLA-4

       5.3.3. Immune System Modulators

       5.3.4. Cancer Vaccines

       5.3.5. Others

   5.4. Market Attractiveness By Therapy 

6. Global Cancer Immunotherapy Market Analysis and Forecasts, By End User 

   6.1. Introduction & Definition

   6.2. Key Findings / Developments

   6.3. Market Value  Forecast By End User, 2021–2031

       6.3.1. Hospitals

       6.3.2. ASC's

       6.3.3. Cancer Research Institutes

       6.3.4. Clinics

   6.4. Market Attractiveness By End User 

7. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapeutic Area 

   7.1. Introduction & Definition

   7.2. Key Findings / Developments

   7.3. Market Value  Forecast By Therapeutic Area, 2021–2031

       7.3.1. Lung Cancer

       7.3.2. Colorectal Cancer

       7.3.3. Breast Cancer

       7.3.4. Prostate Cancer

       7.3.5. Melanoma

       7.3.6. Blood Cancers

       7.3.7. Others

   7.4. Market Attractiveness By Therapeutic Area 

8. Global Cancer Immunotherapy Market Analysis and Forecasts, By Region

   8.1. Key Findings

   8.2. Policies and Regulations

   8.3. Market Value  Forecast By Region

       8.3.1. North America 

       8.3.2. Europe 

       8.3.3. Asia Pacific 

       8.3.4. Latin America 

       8.3.5. Middle East and Africa 

   8.4. Market Attractiveness By Region

9. North America Cancer Immunotherapy Market Analysis and Forecast

   9.1. Introduction

       9.1.1. Key Findings

       9.1.2. Policies and Regulations

   9.2. Market Value Forecast By Therapy Type, 2021–2031

       9.2.1. Monoclonal Antibodies

       9.2.2. Immune Checkpoint Inhibitors

           9.2.2.1. PD-1/PD-L1

           9.2.2.2. CTLA-4

       9.2.3. Immune System Modulators

       9.2.4. Cancer Vaccines

       9.2.5. Others

   9.3. Market Value  Forecast By End User, 2021–2031

       9.3.1. Hospitals

       9.3.2. ASC's

       9.3.3. Cancer Research Institutes

       9.3.4. Clinics

   9.4. Market Value  Forecast By Therapeutic Area, 2021–2031

       9.4.1. Lung Cancer

       9.4.2. Colorectal Cancer

       9.4.3. Breast Cancer

       9.4.4. Prostate Cancer

       9.4.5. Melanoma

       9.4.6. Blood Cancer

       9.4.7. Others

   9.5. Market Value  Forecast By Country, 2021–2031

       9.5.1. U.S.

       9.5.2. Canada

   9.6. Market Attractiveness Analysis 

       9.6.1. By Therapy Type

       9.6.2. By End User 

       9.6.3. By Therapeutic Area 

       9.6.4. By Country

10. Europe Cancer Immunotherapy Market Analysis and Forecast

   10.1. Introduction

       10.1.1. Key Findings

       10.1.2. Policies and Regulations

   10.2. Market Value  Forecast By Therapy Type, 2021–2031

       10.2.1. Monoclonal Antibodies

       10.2.2. Immune Checkpoint Inhibitors

           10.2.2.1. PD-1/PD-L1

           10.2.2.2. CTLA-4

       10.2.3. Immune System Modulators

       10.2.4. Cancer Vaccines

       10.2.5. Others

   10.3. Market Value Forecast By End User, 2021–2031

       10.3.1. Hospitals

       10.3.2. ASC's

       10.3.3. Cancer Research Institutes

       10.3.4. Clinics

   10.4. Market Value Forecast By Therapeutic Area, 2021–2031

       10.4.1. Lung Cancer

       10.4.2. Colorectal Cancer

       10.4.3. Breast Cancer

       10.4.4. Prostate Cancer

       10.4.5. Melanoma

       10.4.6. Blood Cancer

       10.4.7. Others

   10.5. Market Value Forecast By Country, 2021–2031

       10.5.1. Germany

       10.5.2. U.K. 

       10.5.3. France

       10.5.4. Spain

       10.5.5. Italy

       10.5.6. Rest of Europe

   10.6. Market Attractiveness Analysis 

       10.6.1. By Therapy Type

       10.6.2. By End User 

       10.6.3. By Therapeutic Area 

       10.6.4. By Country

11. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast

   11.1. Introduction

       11.1.1. Key Findings

       11.1.2. Policies and Regulations

   11.2. Market Value Forecast By Therapy Type, 2021–2031

       11.2.1. Monoclonal Antibodies

       11.2.2. Immune Checkpoint Inhibitors

           11.2.2.1. PD-1/PD-L1

           11.2.2.2. CTLA-4

       11.2.3. Immune System Modulators

       11.2.4. Cancer Vaccines

       11.2.5. Others

   11.3. Market Value Forecast By End User, 2021–2031

       11.3.1. Hospitals

       11.3.2. ASC's

       11.3.3. Cancer Research Institutes

       11.3.4. Clinics

   11.4. Market Value Forecast By Therapeutic Area, 2021–2031

       11.4.1. Lung Cancer

       11.4.2. Colorectal Cancer

       11.4.3. Breast Cancer

       11.4.4. Prostate Cancer

       11.4.5. Melanoma

       11.4.6. Blood Cancer

       11.4.7. Others

   11.5. Market Value Forecast By Country, 2021–2031

       11.5.1. Japan

       11.5.2. China

       11.5.3. India

       11.5.4. Australia

       11.5.5. New Zealand

       11.5.6. Rest of APAC

   11.6. Market Attractiveness Analysis 

       11.6.1. By Therapy Type

       11.6.2. By End User 

       11.6.3. By Therapeutic Area 

       11.6.4. By Country

12. Latin America Cancer Immunotherapy Market Analysis and Forecast

   12.1. Introduction

       12.1.1. Key Findings

       12.1.2. Policies and Regulations

   12.2. Market Value Forecast By Therapy Type, 2021–2031

       12.2.1. Monoclonal Antibodies

       12.2.2. Immune Checkpoint Inhibitors

           12.2.2.1. PD-1/PD-L1

           12.2.2.2. CTLA-4

       12.2.3. Immune System Modulators

       12.2.4. Cancer Vaccines

       12.2.5. Others

   12.3. Market Value Forecast By End User, 2021–2031

       12.3.1. Hospitals

       12.3.2. ASC's

       12.3.3. Cancer Research Institutes

       12.3.4. Clinics

   12.4. Market Value Forecast By Therapeutic Area, 2021–2031

       12.4.1. Lung Cancer

       12.4.2. Colorectal Cancer

       12.4.3. Breast Cancer

       12.4.4. Prostate Cancer

       12.4.5. Melanoma

       12.4.6. Blood Cancer

       12.4.7. Others

   12.5. Market Value Forecast By Country, 2021–2031

       12.5.1. Brazil

       12.5.2. Mexico

       12.5.3. Rest of Latin America

   12.6. Market Attractiveness Analysis 

       12.6.1. By Therapy Type

       12.6.2. By End User 

       12.6.3. By Therapeutic Area 

       12.6.4. By Country

13. Middle East and Africa Cancer Immunotherapy Market Analysis and Forecast

   13.1. Introduction

       13.1.1. Key Findings

       13.1.2. Policies and Regulations

   13.2. Market Value  Forecast By Therapy Type, 2021–2031

       13.2.1. Monoclonal Antibodies

       13.2.2. Immune Checkpoint Inhibitors

           13.2.2.1. PD-1/PD-L1

           13.2.2.2. CTLA-4

       13.2.3. Immune System Modulators

       13.2.4. Cancer Vaccines

       13.2.5. Others

   13.3. Market Value  Forecast By End User, 2021–2031

       13.3.1. Hospitals

       13.3.2. ASC's

       13.3.3. Cancer Research Institutes

       13.3.4. Clinics

   13.4. Market Value  Forecast By Therapeutic Area, 2021–2031

       13.4.1. Lung Cancer

       13.4.2. Colorectal Cancer

       13.4.3. Breast Cancer

       13.4.4. Prostate Cancer

       13.4.5. Melanoma

       13.4.6. Blood Cancer

       13.4.7. Others

   13.5. Market Value Forecast By Country, 2021–2031

       13.5.1. Saudi Arabia

       13.5.2. UAE

       13.5.3. South Africa

       13.5.4. Rest of MEA

   13.6. Market Attractiveness Analysis 

       13.6.1. By Therapy Type

       13.6.2. By End User 

       13.6.3. By Therapeutic Area 

       13.6.4. By Country

14. Competition Landscape

   14.1. Market Player – Competition Matrix (By Tier and Size of companies)

   14.2. Market Share Analysis By Company (2015)

   14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)

       14.3.1. Amgen, Inc.

           14.3.1.1. Overview

           14.3.1.2. Financials

           14.3.1.3. Recent Developments

           14.3.1.4. Strategy 

       14.3.2. AstraZenca Plc

           14.3.2.1. Overview

           14.3.2.2. Financials

           14.3.2.3. Recent Developments

           14.3.2.4. Strategy

       14.3.3. Bristol-Myers Squibb Company

           14.3.3.1. Overview

           14.3.3.2. Financials

           14.3.3.3. Recent Developments

           14.3.3.4. Strategy

       14.3.4. Eli Lilly and Company

           14.3.4.1. Overview

           14.3.4.2. Financials

           14.3.4.3. Recent Developments

           14.3.4.4. Strategy

       14.3.5. F.Hoffmann-La Roche Ltd.

           14.3.5.1. Overview

           14.3.5.2. Financials

           14.3.5.3. Recent Developments

           14.3.5.4. Strategy

       14.3.6. GlaxoSmithKline Plc.

           14.3.6.1. Overview

           14.3.6.2. Financials

           14.3.6.3. Recent Developments

           14.3.6.4. Strategy

       14.3.7. Janssen Biotech, Inc.

           14.3.7.1. Overview

           14.3.7.2. Financials

           14.3.7.3. Recent Developments

           14.3.7.4. Strategy

       14.3.8. Merck & Co.

           14.3.8.1. Overview

           14.3.8.2. Financials

           14.3.8.3. Recent Developments

           14.3.8.4. Strategy

       14.3.9. Novartis AG

           14.3.9.1. Overview

           14.3.9.2. Financials

           14.3.9.3. Recent Developments

           14.3.9.4. Strategy

       14.3.10. Pfizer, Inc.

           14.3.10.1. Overview

           14.3.10.2. Financials

           14.3.10.3. Recent Developments

           14.3.10.4. Strategy

       14.3.11. Sanofi

           14.3.11.1. Overview

           14.3.11.2. Financials

           14.3.11.3. Recent Developments

           14.3.11.4. Strategy

       14.3.12. Spectrum Pharmaceuticals, Inc.

           14.3.12.1. Overview

           14.3.12.2. Financials

           14.3.12.3. Recent Developments

           14.3.12.4. Strategy

       14.3.13. Takeda Pharmaceuticals

           14.3.13.1. Overview

           14.3.13.2. Financials

           14.3.13.3. Recent Developments

           14.3.13.4. Strategy

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031

Table 2: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, By Therapy Type (Immune Checkpoint Inhibitors), 2021–2031

Table 3: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2021–2031

Table 4: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031

Table 5: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2021–2031

Table 6: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031

Table 7: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2021–2031

Table 8: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2021–2031

Table 9: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031

Table 10: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031

Table 11: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031

Table 12: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2021–2031

Table 13: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2021–2031

Table 14: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031

Table 15: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031

Table 16: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031

Table 17: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031

Table 18: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2021–2031

Table 19: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2021–2031

Table 20: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031

Table 21: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031

Table 22: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031

Table 23: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2021–2031

Table 24: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapeutic Area, 2021–2031

Table 25: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031

Table 26: Latin America Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031

Table 27: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type, 2021–2031

Table 28: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Therapy Type (Immune Checkpoint Inhibitors), 2021–2031

Table 29: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by End-User, 2021–2031

Table 30: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2021–2031

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 1: Global Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 2: Global Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031

Figure 3: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Monoclonal Antibodies, 2021–2031

Figure 4: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune Checkpoint Inhibitors, 2021–2031 

Figure 5: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Immune System Modulators, 2021–2031

Figure 6: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Vaccines, 2021–2031 

Figure 7: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Others, 2021–2031

Figure 8: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type

Figure 9: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By PD-1/PD-L1 Type, 2021–2031

Figure 10: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By CTLA-4 Type, 2021–2031 

Figure 11: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type (Immune Checkpoint Inhibitors)

Figure 12: Global Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 13: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area

Figure 14: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Lung Cancer, 2021–2031

Figure 15: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Colorectal Cancer, 2021–2031 

Figure 16: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Breast Cancer, 2021–2031

Figure 17: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Prostate Cancer, 2021–2031

Figure 18: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Melanoma, 2021–2031

Figure 19: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Blood Cancers, 2021–2031 

Figure 20: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Other Cancers, 2021–2031

Figure 21: Global Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031

Figure 22: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Hospitals, 2021–2031

Figure 23: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By ASC’s, 2021–2031

Figure 24: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cancer Research Institutes, 2021–2031

Figure 25: Global Cancer Immunotherapy Market Revenue (US$ Mn) and Y-o-Y growth (%), By Clinics, 2021–2031 

Figure 26: Global Cancer Immunotherapy Market Attractiveness Analysis, by End-User

Figure 27: Global Cancer Immunotherapy Market Value Share Analysis, by Region, 2021 and 2031

Figure 28: Global Cancer Immunotherapy Market Attractiveness Analysis, by Region

Figure 29: North America Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 30: North America Cancer Immunotherapy Market Attractiveness Analysis By Country

Figure 31: North America Market Value Share Analysis, by Therapy Type, 2021 and 2031

Figure 32: North America Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 33: North America Market Value Share Analysis, by End-User, 2021 and 2031

Figure 34: North America Market Value Share Analysis, by Country, 2021 and 2031

Figure 35: U.S. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 36: U.S. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 37: Canada Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 38: Canada Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 39: North America Cancer Immunotherapy Market Attractiveness by Therapy Type

Figure 40: North America Cancer Immunotherapy Market Attractiveness by Therapeutic Area

Figure 41: North America Cancer Immunotherapy Market Attractiveness by End-User

Figure 42: Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 43: Europe Cancer Immunotherapy Market Attractiveness Analysis by Country

Figure 44: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031

Figure 45: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 46: Europe Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031

Figure 47: Europe Cancer Immunotherapy Market Value Share Analysis, by Country, 2021 and 2031

Figure 48: Germany Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 49: Germany Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 50: U.K. Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 51: U.K. Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 52: France Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 53: France Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 54: Spain Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 55: Spain Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 56: Italy Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 57: Italy Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 58: Rest of Europe Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 59: Rest of Europe Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 60: Europe Cancer Immunotherapy Market Attractiveness by Therapy Type

Figure 61: Europe Cancer Immunotherapy Market Attractiveness by Therapeutic Area 

Figure 62: Europe Cancer Immunotherapy Market Attractiveness by End-User

Figure 63: Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 64: Asia Pacific Cancer Immunotherapy Market Attractiveness Analysis, By Country

Figure 65: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031

Figure 66: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031

Figure 67: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031

Figure 68: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Country, 2021 and 2031

Figure 69: Japan Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 70: Japan Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 71: China Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 72: China Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 73: India Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 74: India Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 75: Australia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 76: Australia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 77: New Zealand Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 78: New Zealand Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 79: Rest of Asia Pacific Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 80: Rest of Asia Pacific Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 81: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapy Type

Figure 82: Asia Pacific Cancer Immunotherapy Market Attractiveness by Therapeutic Area

Figure 83: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User

Figure 84: Asia Pacific Cancer Immunotherapy Market Attractiveness by End-User

Figure 85: Latin America Cancer Immunotherapy Market Attractiveness Analysis by Country

Figure 86: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031

Figure 87: Latin America Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 88: Latin America Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031

Figure 89: Latin America Cancer Immunotherapy Market Value Share Analysis, by Country, 2021 and 2031

Figure 90: Brazil Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 91: Brazil Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 92: Mexico Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 93: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 94: Mexico Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 95: Rest of Latin America Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 96: Latin America Cancer Immunotherapy Market Attractiveness by Therapy Type

Figure 97: Latin America Cancer Immunotherapy Market Attractiveness by Therapeutic Area

Figure 98: Latin America Cancer Immunotherapy Market Attractiveness by End-User

Figure 99: Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 100: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis by Country

Figure 101: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2021 and 2031

Figure 102: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 103: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031

Figure 104: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by End-User, 2021 and 2031

Figure 105: Saudi Arabia Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 106: Saudi Arabia Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 107: UAE Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 108: UAE Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 109: RSA Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 110: RSA Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 111: Rest of Middle East & Africa Cancer Immunotherapy Market Size (US$ Mn) Forecast, 2021–2031

Figure 112: Rest of Middle East & Africa Cancer Immunotherapy Market Absolute $ Opportunity (US$ Mn), 2021–2031

Figure 113: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapy Type

Figure 114: Middle East & Africa Cancer Immunotherapy Market Attractiveness by Therapeutic Area

Figure 115: Middle East & Africa Cancer Immunotherapy Market Attractiveness by End-User

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Cancer Immunotherapy Market

Schedule a Call